这篇论文用一个改进的损失函数让药物相互作用预测准了将近20个百分点，读来很有启发。
论文提出ClinicalFocal损失函数，集成到关系感知图卷积网络（RGCN）中，用于预测药物-药物相互作用。在TWOSIDES数据集上，五折交叉验证下，该方法将准确率从0.699提升至0.892（+19.3个百分点），F1分数从0.700提升至0.894。AUROC从0.766升至0.914，AUCPR从0.714升至0.860。假阴性率从29.8%降至9.1%，特异性从69.6%增至87.5%，整体分类错误降低64.1%。
Asymmetric Focal Loss Improves Graph Neural Network Prediction of Drug-Drug Interactions
Background: Graph neural networks improve computational prediction of polypharmacy side effects, but standard binary cross-entropy training allocates equal capacity to well-classified and difficult examples, potentially missing clinically significant interactions. We evaluated whether an asymmetric focal objective could improve multi-relational drug-drug interaction (DDI) prediction by emphasizing difficult positive interactions. Methods: ClinicalFocal loss was integrated into a relation-aware graph convolutional network using molecular fingerprints, physicochemical descriptors, and learned embeddings. The model was evaluated on TWOSIDES using five-fold cross-validation with identical experimental conditions (architecture, features, data partitions, hyperparameters, and random seeds) for ClinicalFocal loss and binary cross-entropy baseline. Results: ClinicalFocal loss increased accuracy from 0.699 to 0.892 (+19.3 percentage points) and F1 score from 0.700 to 0.894 (+19.4 percentage points). AUROC increased from 0.766 to 0.914, and AUCPR increased from 0.714 to 0.860. The false-negative rate decreased from 29.8% to 9.1%, while specificity increased from 69.6% to 87.5%. Overall classification error decreased from 30.1% to 10.8%, corresponding to a 64.1% relative reduction. Improvements were consistent across all five folds. Conclusions: Asymmetric focal optimization improved classification and ranking performance while achieving 90.9% recall for observed interaction triples, without modifying the underlying architecture. Loss-function design is a direct, tunable lever for improving graph-based DDI prediction.